ライフサイエンスコーパス: subfoveal

1 was within 15 letters of baseline after the subfoveal AAV2-hCHM injections in 13 of 15 patients.

2 Immunohistochemistry showed subfoveal accumulation of retinal pigment epithelial cel

3 Twenty percent of incident GA lesions were subfoveal and an additional 18% were within 250 mum of t

4 Subfoveal and average choroidal thickness in the central

5 Both subfoveal and average choroidal thicknesses were associa

6 was 0.95 (74.1 mum) and 0.96 (63.9 mum) for subfoveal and average CT, respectively.

7 ontinuous unilateral anti-VEGF treatment for subfoveal and juxtafoveal neovascular AMD and a minimum

8 ion and choroidal neovascularization that is subfoveal and predominately classic (> 50%).

9 However, subfoveal and temporal choroidal area thickness signific

10 .0001) and external limiting membrane in the subfoveal area (P < .0001) at baseline were the only 2 i

11 (all P-values < 0.001), as well as RT in the subfoveal area (P-value < 0.001) and 1500 mum nasal to t

12 roidal thicknesses in the temporal and nasal subfoveal areas were measured using enhanced-depth imagi

13 Subfoveal AVLs were most common, observed in 79% of case

14 Subfoveal center point choroidal thickness, mean central

15 Significant difference of subfoveal center point measurement or mean of central mi

16 No significant difference between subfoveal center point measurement/mean of choroidal thi

17 ne scan can represent the entire choroid but subfoveal center point measurements are only indicative

18 artile range, 0-27 months) before detectable subfoveal changes.

19 Similar pausing behavior was observed in the subfoveal choriocapillaris.

20 such as subfoveal choroidal thickness (SCT), subfoveal choriocapillary thickness (SCCT), central macu

21 t study was to investigate whether a thinner subfoveal choroid at 11 years of age predicted axial eye

22 A thin subfoveal choroid at age 11 years did not predict axial

23 wed a normal retina in all patients, but the subfoveal choroid in the hypopigmented region was slight

24 Subfoveal choroid may thicken and remodel in response to

25 Eyes with PSF showed significantly thicker subfoveal choroid than eyes without PSF (305+/-61 mum vs

26 The subfoveal choroid was a mean 23% thicker in the involved

27 A thicker baseline subfoveal choroid was associated with increased five-yea

28 In addition, the response of subfoveal choroidal blood flow (-6.2% +/- 3.2%; P = 0.00

29 Subfoveal choroidal blood flow and fundus pulsation ampl

30 All patients had a subfoveal choroidal neovascular membrane with or without

31 adhesion molecule (ICAM)-1 and E-selectin in subfoveal choroidal neovascular membranes (CNVMs) surgic

32 ted macular degeneration secondary to active subfoveal choroidal neovascularisation, with best correc

33 ty-six cases of previously untreated, active subfoveal choroidal neovascularization (CNV) associated

34 Eyes with subfoveal choroidal neovascularization (CNV) lesions had

35 y and Safety of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization (CNV) Secondary t

36 Patients with subfoveal choroidal neovascularization (CNV) secondary t

37 A total of 151 patients with subfoveal choroidal neovascularization (CNV) secondary t

38 During a 4-month period, 29 patients with subfoveal choroidal neovascularization (CNV), who were e

39 anibizumab in patients with treatment-naive, subfoveal choroidal neovascularization caused by neovasc

40 sis study evaluated photodynamic therapy for subfoveal choroidal neovascularization caused by presume

41 re collected from 1134 of 1146 patients with subfoveal choroidal neovascularization due to AMD with m

42 reduce the risk of visual loss in eyes with subfoveal choroidal neovascularization from age-related

43 nally, submacular surgery for the removal of subfoveal choroidal neovascularization has promising res

44 rgery or observation is better for eyes with subfoveal choroidal neovascularization in presumed ocula

45 site of the laser photocoagulation scar, and subfoveal choroidal neovascularization is not amenable t

46 n age-related macular degeneration eyes with subfoveal choroidal neovascularization is uniform across

47 us with the first realistic means to address subfoveal choroidal neovascularization lesions from age-

48 ding center of patients with treatment-naive subfoveal choroidal neovascularization receiving intravi

49 Patients with active subfoveal choroidal neovascularization secondary to age-

50 hase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD

51 Treatment-naive patients with active subfoveal choroidal neovascularization secondary to nAMD

52 epithelial detachment associated with occult subfoveal choroidal neovascularization with intravitreal

53 y and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization with or without C

54 Therefore, it allows the clinician to treat subfoveal choroidal neovascularization without immediate

55 mise for selected conditions (in particular, subfoveal choroidal neovascularization), the optimal tec

56 of 8.1% for the average person with classic subfoveal choroidal neovascularization, while laser phot

57 : Total of 255 treatment-naive patients with subfoveal choroidal neovascularization.

58 teporfin is approved for treatment of occult subfoveal choroidal neovascularization.

59 (28 eyes) tended to have a greater baseline subfoveal choroidal thickness (239 +/- 12 mum) than the

60 to 153.64 +/- 100.25 microns, P = 0.034) and subfoveal choroidal thickness (372.92 +/- 83.84 to 342.8

61 Emmetropic eyes tended to have thicker subfoveal choroidal thickness (381.94 +/- 79.88 mum vs 3

62 ration (beta: - 0.05; P = 0.04), and thicker subfoveal choroidal thickness (beta: 0.08; P < 0.001).

63 ale sex (beta: 0.15; P < 0.001), and thicker subfoveal choroidal thickness (beta: 0.24; P < 0.001).

64 ckness (IRT), outer retinal thickness (ORT), subfoveal choroidal thickness (CT), temporal and nasal C

65 led no significant difference in the average subfoveal choroidal thickness (P > 0.05) among systems f

66 outer nuclear layer thickness (P = .02), and subfoveal choroidal thickness (P = .003) at follow-up vs

67 y (P = .022), and negatively associated with subfoveal choroidal thickness (P = .031) and presence of

68 onarteritic AION was associated with thinner subfoveal choroidal thickness (P = 0.007) after adjustin

69 N as compared to control eyes showed thinner subfoveal choroidal thickness (P = 0.037) after adjustin

70 12.4 vs male 55.1 +/- 11.3) and had thinner subfoveal choroidal thickness (p = 3.8 x 10(-5)) and hig

71 01), pseudophakia (P = 0.03), and decreasing subfoveal choroidal thickness (r = -0.27; P = 0.003).

72 Subfoveal choroidal thickness (SCT) was measured using t

73 Central macular thickness (CMT), subfoveal choroidal thickness (SCT), retinal nerve fiber

74 For each eye parameters such as subfoveal choroidal thickness (SCT), subfoveal choriocap

75 In addition, the subfoveal choroidal thickness (SFChT), anterior chamber

76 shown in mean BCVA (0.58 0.28 vs 0.77 0.31), subfoveal choroidal thickness (SFCT) (108.17 78.32 um vs

77 Subfoveal choroidal thickness (SFCT) and choroidal thick

78 Subfoveal choroidal thickness (SFCT) and peripapillary c

79 o simultaneously evaluate iris area (IA) and subfoveal choroidal thickness (SFCT) in eyes with Fuchs

80 essing choroidal vascularity index (CVI) and subfoveal choroidal thickness (SFCT) in these patients.

81 Subfoveal choroidal thickness (SFCT) in young-preterm in

82 Drusen subtypes, fibrosis, atrophy and subfoveal choroidal thickness (SFCT) of both eyes in pat

83 ce, two experienced OCT readers measured the subfoveal choroidal thickness (SFCT) of the horizontal a

84 Subfoveal choroidal thickness (SFCT) was measured by 2 m

85 ution at 1 and 3 months, mean change in CMT, subfoveal choroidal thickness (SFCT), best-corrected vis

86 kness (CMT) and choroidal features including subfoveal choroidal thickness (SFCT), total choroidal ar

87 l area (SA), total choroidal area (TCA), and subfoveal choroidal thickness (SFCT), were evaluated usi

88 vided into 3 groups according to the initial subfoveal choroidal thickness (SFCT).

89 urysms within/at the margins of the CNV, and subfoveal choroidal thickness (SFCT).

90 acular central subfield thickness (CST), and subfoveal choroidal thickness (SFCT).

91 acular central subfield thickness (CST), and subfoveal choroidal thickness (SFCT).

92 terior BM pole, i.e., induces changes in the subfoveal choroidal thickness (SFCT).

93 f the LLQ scores and age, RIT, AMD severity, subfoveal choroidal thickness [SFCT], phakic status, and

94 The decrease in subfoveal choroidal thickness after anti-VEGF treatment

95 A negative correlation between subfoveal choroidal thickness and age was detected in al

96 Strong correlations between subfoveal choroidal thickness and axial length and myopi

97 erence tomography scans were used to measure subfoveal choroidal thickness and central macular thickn

98 On the initial presentation, age, subfoveal choroidal thickness and central retinal thickn

99 Mean subfoveal choroidal thickness and mean subfoveal medium

100 The subfoveal choroidal thickness and the subfoveal medium c

101 Subfoveal choroidal thickness and was measured using enh

102 inal atrophy, central retinal thickness, and subfoveal choroidal thickness are likely to be valuable

103 Subfoveal choroidal thickness at 11 years of age did not

104 After 3 monthly anti-VEGF treatments, subfoveal choroidal thickness decreased significantly (2

105 Subfoveal choroidal thickness decreased significantly in

106 Subfoveal choroidal thickness decreased with age, wherea

107 The subfoveal choroidal thickness did not vary between ethni

108 ruited via stratified randomisation based on subfoveal choroidal thickness from the Singapore Epidemi

109 In this study, eyes with a thicker baseline subfoveal choroidal thickness had better short-term anat

110 rols (331 mum +/- 24; mean +/- 95% CI), mean subfoveal choroidal thickness in eyes of patients with P

111 This study found reduced iris area and subfoveal choroidal thickness in eyes with FUS compared

112 The estimation of the variation in the subfoveal choroidal thickness in relationship to the axi

113 ubretinal fluid is associated with increased subfoveal choroidal thickness in surgical and fellow eye

114 Mean subfoveal choroidal thickness in the bullous CSC group (

115 the most significant factor associated with subfoveal choroidal thickness in the entire group, follo

116 f the central macular subfield and 35 mum in subfoveal choroidal thickness is necessary to detect tru

117 Baseline subfoveal choroidal thickness may help predict which pat

118 Subfoveal choroidal thickness measured with EDI-OCT was

119 We evaluated subfoveal choroidal thickness measured with two differen

120 Manual subfoveal choroidal thickness measurements were made by

121 Subfoveal choroidal thickness obtained with two differen

122 In the entire group the mean subfoveal choroidal thickness of those without loculated

123 sion was used to evaluate the association of subfoveal choroidal thickness or average choroidal thick

124 f the subfoveal fluid and a reduction of the subfoveal choroidal thickness to 271 mum after a 3 month

125 volume, and scleral sink, along with higher subfoveal choroidal thickness values compared to both Gr

126 t was used to assess the correlation between subfoveal choroidal thickness values determined by the t

127 Mean subfoveal choroidal thickness was 156 mum (147, 42-362 m

128 Mean (SD) subfoveal choroidal thickness was 332 (90) mum (right ey

129 The intrasession CR of subfoveal choroidal thickness was 34.7 mum (95% CI 33.7-

130 Mean subfoveal choroidal thickness was 345.67 +/- 81.80 mum a

131 Mean subfoveal choroidal thickness was 381 mum (standard devi

132 ween the perivascular stromal tissue and the subfoveal choroidal thickness was 66% in the study eye a

133 te analyses revealed that a greater baseline subfoveal choroidal thickness was associated with a bett

134 In multivariate analysis, thinner subfoveal choroidal thickness was associated with the di

135 Subfoveal choroidal thickness was compared with matched

136 Subfoveal choroidal thickness was greater in patients wi

137 Subfoveal choroidal thickness was measured as the distan

138 pectral-domain optical coherence tomography; subfoveal choroidal thickness was measured manually usin

139 Subfoveal choroidal thickness was measured using EDI-OCT

140 Baseline subfoveal choroidal thickness was not significantly diff

141 A significant reduction in subfoveal choroidal thickness was noted after anti-VEGF

142 that choroidal melanocytosis shows increased subfoveal choroidal thickness with an apparent increase

143 In the myopic group, the variation in the subfoveal choroidal thickness with the myopic refractive

144 layer thickness, central subfield thickness, subfoveal choroidal thickness, total choroidal area, lum

145 illar, focal choroidal excavation (FCE), and subfoveal choroidal thickness, with a P value of < 0.05

146 l length, disc-fovea distance, age, sex, and subfoveal choroidal thickness.

147 presence of RPD, AMD severity, and decreased subfoveal choroidal thickness.

148 using a DRI SS OCT, and line measurements of subfoveal choroidal thicknesses (SFCT) were also perform

149 velopment and validation datasets, with mean subfoveal choroidal thicknesses of 307 and 293 microm, r

150 Based on average and subfoveal choroidal thicknesses, the choroid of eyes wit

151 Subfoveal ChT was 315 +/- 106 mum (mean +/- SD), negativ

152 proximately 1500 mum inferior, compared with subfoveal ChT.

153 Older age, subfoveal CNV location, and larger baseline lesion size

154 Autorefraction in patients with subfoveal CNV may be a satisfactory alternative to manif

155 zumab, Study of Ranibizumab in Patients with Subfoveal CNV Secondary to AMD, Extension Study to Evalu

156 Eleven subjects with occult subfoveal CNVM due to AMD were assessed in a masked fash

157 In subfoveal CNVMs from patients with AMD, there is increas

158 localization of ICAM-1 and E-selectin in 10 subfoveal CNVMs was determined by immunohistochemistry.

159 eam radiation therapy in seven fractions for subfoveal CNVMs were found to have recurrent or persiste

160 Subfoveal CSJ was visualized in 96% of young-preterm inf

161 Regression analysis suggested that subfoveal CT decreased by 11.9 mum for each decade of li

162 A difference of 74.1 mum in subfoveal CT or 63.9 mum in average CT may be necessary

163 Subfoveal CT showed persistent thinning from normal grou

164 The mean subfoveal CT was 118 mum (+/- 68 mum) and correlated neg

165 The subfoveal CT was 213.7 +/- 86.6 mum in the study eyes an

166 Subfoveal CT was 297.8 +/- 82.2 mum, which did not diffe

167 For pFTLD-Tau, pADNC, and controls, the subfoveal CT was 308.9, 286.0, and 301.5 mum, and CVI wa

168 The subfoveal CT was inversely correlated with the logMAR vi

169 Subfoveal CT was measured using 3 different posterior bo

170 Subfoveal CT was measured via Optical Coherence Tomograp

171 and a significant positive correlation with subfoveal CT, temporal and nasal CT, and FAZ diameter (P

172 of myopia, whereas visual acuity depends on subfoveal CT.

173 ual acuity decreases in line with decreasing subfoveal CT.

174 SpCas9 regardless of gRNA presence developed subfoveal deposits, concentric macular rings, and outer

175 Before surgery, a subfoveal detachment (SD) corresponding to the yellow de

176 Subfoveal detachments do not affect visual outcome and s

177 Subfoveal detachments secondary to idiopathic ERM were o

178 f age 50% of patients would have discernible subfoveal ellipsoid zone.

179 in an uncomplicated pregnancy with extensive subfoveal exudates and severe permanent visual loss.

180 he subretinal fluid and the disappearance of subfoveal exudates.

181 ase and that there is a subclinical stage of subfoveal exudation ('preoccult') for patients with age-

182 igher baseline BCVA, and a definitely intact subfoveal EZ are predictors of BCVA score > 70 letters a

183 ion (CE, 0.72; 95% CI, 0.03-1.42; P = 0.04), subfoveal EZ disruption (CE, 0.62; 95% CI, 0.02-1.23; P

184 lood circulation alterations than those with subfoveal EZ loss only.

185 no statistically significant association of subfoveal EZ loss with BCVA.

186 he prespecified OCT parameters were DRIL and subfoveal EZ loss.

187 OCT features of subfoveal fibrosis and the overlying retina were correla

188 in age-related macular degeneration without subfoveal fibrosis at first presentation who were treate

189 Subfoveal fibrosis at the conclusion follow-up of 24 mon

190 The hazard ratio of any subfoveal fibrosis developing in eyes with predominantly

191 The development of subfoveal fibrosis in neovascular age-related macular de

192 In 83 eyes that had subfoveal fibrosis, better vision was associated with in

193 cause of severe atrophic macular changes and subfoveal fibrosis, no improvement of visual acuity was

194 retinal fluid (16.3% vs 6.4%, p = 0.04), and subfoveal fluid (16.3% vs. 3.2%, p = 0.003).

195 NSD was defined as subfoveal fluid accumulation under detached retina with

196 Transient subfoveal fluid accumulation was noted in all these pati

197 One patient had subfoveal fluid alone, and 1 patient had peripapillary s

198 Grade 3 included subfoveal fluid along with grade 2 traits.

199 EDI-OCT showed resolution of the subfoveal fluid and a reduction of the subfoveal choroid

200 Similarly, 33.3% (5/15) developed residual subfoveal fluid blebs (delayed progression to stage 3).

201 eoschisis and foveal detachment in which the subfoveal fluid had spontaneously resolved.

202 ome healthy full-term infants have bilateral subfoveal fluid not obvious on dilated retinal examinati

203 Six (15%) of the 39 infants had bilateral subfoveal fluid on SD OCT not seen by indirect ophthalmo

204 ses had parafoveal fluid (of whom 9 also had subfoveal fluid).

205 r vitreous hyperreflective dots, and minimal subfoveal fluid, all of which corresponded to areas of r

206 ts were mild foveal thickening and prominent subfoveal fluid, and those in sham-treated patients were

207 ities, such as outer retinal folds, residual subfoveal fluid, or retinal displacement, with rapid rec

208 rom 20/20 to 20/200 after the development of subfoveal fluid.

209 RPE compartments for risk stratification for subfoveal GA (sfGA) progression.

210 l eyes, including eyes with nonsubfoveal and subfoveal GA, pegcetacoplan reduced the mean rate of cha

211 area, number of GA lesions, and presence of subfoveal GA, the mean annual change in GA area was 0.27

212 subfoveal) GA lesions and tended to increase as baseline

213 t epithelium (RPE) atrophy/absence in 22.9%, subfoveal geographic atrophy in 2.5%, and fluid in or un

214 of the subretinal tissue complex on OCT, and subfoveal geographic atrophy or scar on FP/FA had the wo

215 2D CVI (Subfoveal) had a moderate agreement with 3D CVI (Central

216 esented with acute loss of vision owing to a subfoveal hemorrhage secondary to neovascular age-relate

217 ysiology of ocular diseases characterized by subfoveal hypoxia and VEGF upregulation, such as age-rel

218 n size was 0.82 disc area (DA); lesions were subfoveal in 40.5%, occult CNV composition was present i

219 nt in 213 of 515 (41%) gradable eyes and was subfoveal in 85 eyes (17%).

220 The maximal choroidal thickness was subfoveal in 9 of 41 eyes (22%), focal choroidal thinnin

221 Patients received subfoveal injection of AAV2-REP1 (10(11) genome particle

222 Five patients who received a single subfoveal injection of AAV2-REP1 were studied.

223 d AAV.REP1 (0.6-1.0x10(10) genome particles, subfoveal injection).

224 Patients received uniocular subfoveal injections of low-dose (up to 5 x 10(10) vecto

225 dy participants must have received uniocular subfoveal injections of low-dose or high-dose AAV2-hCHM.

226 All patients had subfoveal involvement with choroidal melanocytosis.

227 With subfoveal, juxtafoveal, or extrafoveal choroidal neovasc

228 cept injections as the primary treatment for subfoveal/juxtafoveal myopic choroidal neovascularizatio

229 21 treatment-naive eyes of 21 patients with subfoveal/juxtafoveal myopic CNV received primary intrav

230 subfoveal total choroidal thickness and mean subfoveal large choroidal vessel layer thickness were si

231 y correlated with the rate of BCVA loss with subfoveal lesions at high risk of vision loss over time,

232 namic therapy has also proved beneficial for subfoveal lesions secondary to high myopia.

233 reatment-naive neovascular AMD patients with subfoveal lesions were treated and examined monthly for

234 Subfoveal lesions, a thicker Haller's layer, and increas

235 ocular histoplasmosis, in particular that of subfoveal localization.

236 pic eyes was thickest temporally compared to subfoveal location in emmetropic subjects (thickest poin

237 The subfoveal choroidal thickness and the subfoveal medium choroidal vessel layer and choriocapill

238 Mean subfoveal choroidal thickness and mean subfoveal medium choroidal vessel layer and choriocapill

239 Risk factors were subfoveal mMNV location (HR [95% CI] = 12.7 [2.70-56.7]

240 nts in the HARBOR trial with nAMD and active subfoveal MNV, a total of 922 study eyes and 919 fellow

241 pants included treatment-naive patients with subfoveal nAMD and PEDs at baseline; intervention arms w

242 e reviewed 917 patients 50 years of age with subfoveal nAMD associated with subretinal (SRF) and/or i

243 reviewed 917 patients >=50 years of age with subfoveal nAMD associated with subretinal (SRF) and/or i

244 Average, subfoveal, nasal, and temporal choroidal thicknesses wer

245 on an as-needed Basis (PRN) in patients with subfoveal neOvasculaR age-related macular degeneration (

246 ly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (

247 on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration).

248 ty eyes of 120 patients with treatment-naive subfoveal neovascular AMD participated in this study at

249 0 years were eligible if they presented with subfoveal neovascular AMD, with best-corrected visual ac

250 eyes with diabetic macular edema (DME) with subfoveal neuroretinal detachment (SND+) vs DME without

251 In 3 patients OCT revealed subfoveal neuroretinal elevation, often asymptomatic, al

252 the detailed clinical findings of bilateral subfoveal neurosensory retinal detachment associated wit

253 ived oral MEK inhibitors developed bilateral subfoveal neurosensory retinal detachment.

254 s may prompt the ophthalmologist to consider subfoveal neurosensory retinal detachment.

255 We report on a series of bilateral subfoveal neurosensory retinal detachments in patients w

256 on, although a large minority of lesions are subfoveal or multifocal at initial detection.

257 Among 605 patients with subfoveal or nonsubfoveal GA, treatment with pegcetacopl

258 atients (4 eyes) had "severe" injuries, with subfoveal outer retinal architecture loss and overlying

259 he mean choroidal thickness was lower in the subfoveal (P = .006) and nasal 3000-um-diameter areas (P

260 ever, there was no significant difference in subfoveal (P = .675) or average choroidal thickness (P =

261 No significant differences were found in subfoveal (p = 0.659), temporal, and nasal CT values in

262 of eyes varied substantially by the type of subfoveal pathology on FP and FA: 70.6 for no pathology;

263 in visual acuity (VA) after reabsorption of subfoveal pigment epithelial detachments (PED).

264 th age-related macular degeneration who have subfoveal predominately classic choroidal neovasculariza

265 in photodynamic therapy for the treatment of subfoveal, predominately classic, choroidal neovasculari

266 ed treatment approach (92%) and avoidance of subfoveal region (89%).

267 The CT was measured at the subfoveal region in a horizontal fashion, 3 mm temporal

268 Similar results were observed for the subfoveal region.

269 scularity index (CVI) were calculated in the subfoveal region.

270 To investigate the subfoveal retinal and choroidal thickness in patients wi

271 cancer, with bilateral uveitis and bilateral subfoveal retinal detachment.

272 Subfoveal retinal thickness decreased significantly only

273 Additionally, subfoveal retinal thickness, retinal nerve fiber layer (

274 0.7 mum per month (-0.4 to 1.8; P = .20) for subfoveal retinal thickness.

275 (70%) and decreased in 12 (30%), related to subfoveal scar, persistent subretinal fluid, reactive ex

276 esion typically developed at the apex of the subfoveal serous cavity or along its lateral edges, begi

277 Fundus examination showed subfoveal severe exudation with a posterior pole serous

278 s central retinal thickness (CRT), height of subfoveal sub-retinal fluid (SRF), central choroid thick

279 Furthermore, CT was measured in the subfoveal, temporal, and nasal positions at 500-um inter

280 al fluid, pigment epithelial detachment, and subfoveal thickening.

281 Subfoveal thickness and choroidal volume were measured w

282 The subfoveal thickness difference was -4.1 mum on horizonta

283 anatomical (i.e., central subfoveal thickness, CST; presence of fluid), functional

284 of subretinal thickening (P = .003), intact subfoveal third hyperreflective band (P = .006), and int

285 Mean subfoveal total choroidal thickness and mean subfoveal l

286 tiles had accelerated BCVA loss in eyes with subfoveal, unifocal lesions.

287 yes where the SCL was not visible, mean [SD] subfoveal VCT was 222.3 [101.5] mum and StCT and TCT wer

288 In eyes where the SCL was visible, mean [SD] subfoveal VCT, StCT, and TCT were 221.9 [83.1] mum, 257.

289 3D CVI (Whole Macula) and 2D CVI (Subfoveal) were associated only with each other and not

290 Patients aged >/=50 years with subfoveal wet age-related macular degeneration (AMD) who